Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sangha, O.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sangha, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 3-12
© 2000 British Society for Rheumatology

SUPPLEMENT

Epidemiology of rheumatic diseases

O. Sangha

University of Munich, Faculty of Medicine, Bavarian Public Health Research Center, Munich, Germany

Correspondence to: Correspondence to: O. Sangha, University of Munich, Faculty of Medicine, Bavarian Public Health Research Center, Tegernseer Landstrasse 243, D-81549 Munich, Germany.

Abstract

Rheumatic diseases are among the oldest diseases recognized. The classification of rheumatic diseases is sometimes difficult due to unknown aetiology and heterogeneity in their clinical presentation. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common rheumatic diseases, accounting for a large percentage of disability worldwide. The economic and social burden of these diseases is great. Their impact on both individuals and society results from a decreased quality of life, lost productivity and increased costs of health care. Without appropriate approaches to patient management and control of these diseases, this impact can be expected to increase as the population ages. One of the challenges in studying OA and RA, and rheumatic diseases in general, is deriving epidemiological data that can be used to understand better the factors that contribute to the initiation and progression of these diseases. Only with such an understanding can significant progress be made in the diagnosis, treatment and management of patients.

KEY WORDS: Osteoarthritis, Rheumatoid arthritis, Epidemiology, Disease burden, Health outcomes, NSAIDs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Meune, E. Touze, L. Trinquart, and Y. Allanore
Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies
Rheumatology, October 1, 2009; 48(10): 1309 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
S. Brien, P. Prescott, and G. Lewith
Meta-analysis of the Related Nutritional Supplements Dimethyl Sulfoxide and Methylsulfonylmethane in the Treatment of Osteoarthritis of the Knee
Evid. Based Complement. Altern. Med., May 27, 2009; (2009) nep045v1.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
S. Brien, P. Prescott, B. Coghlan, N. Bashir, and G. Lewith
Systematic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis
QJM, March 1, 2008; 101(3): 167 - 179.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.